The good news is these medications, semaglutide, the active ingredient in Ozempic and Wegovy, or tirzepatide, the active ingredient in Mounjaro, are part of a class of medications, GLP-1 receptor agonists, that have been around for over 20 years so we know the side effects, mostly gastrointestinal in nature (nausea, vomiting, constipation and diarrhea)
By enhancing natural satiety signals, it helps: reduce cravings decrease food intake support healthier eating patterns This mechanism plays a major role in adults using WEGOVY 0.25MG INJECTION for weight-related goals under medical supervision
None of the analyses demonstrated an increased risk of PDAC associated with GLP-1RA 35,36,37 (Table 1)
Rienstra, M
Comedians talk about it, joke about how everyone in Hollywood is on this medication, said Matthew Gilbert, an endocrinology professor at the University of Vermont Larner College of Medicine